Page last updated: 2024-08-16

propranolol and gdc 0941

propranolol has been researched along with gdc 0941 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beaufils, F; Bohnacker, T; Borsari, C; Cmiljanovic, N; Cmiljanovic, V; Fabbro, D; Giese, B; Hebeisen, P; Hillmann, P; Jackson, E; Marone, R; Melone, A; Mestan, J; Rageot, D; Sele, A; Williams, RL; Wymann, MP; Zhang, X; Zvelebil, M	1

Other Studies

1 other study(ies) available for propranolol and gdc 0941

Article	Year
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17 Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Brain; Cell Proliferation; Dogs; Humans; Mice; Models, Molecular; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Rats; Rats, Nude; Signal Transduction; TOR Serine-Threonine Kinases	2017

Article

Year

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology.

Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

Topics: Administration, Oral; Aminopyridines; Animals; Antineoplastic Agents; Brain; Cell Proliferation; Dogs; Humans; Mice; Models, Molecular; Morpholines; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Rats; Rats, Nude; Signal Transduction; TOR Serine-Threonine Kinases

2017